These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24701698)

  • 21. Animal models for personalized treatment options.
    Fichtner I; Klinghammer K; Behrens D; Flechsig S; Rolff J; Becker M; Wulf-Goldenberg A; Stecklum M; Rivera M; Brzezicha B; Jandrig B; Hoffmann J
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):698-700. PubMed ID: 28696202
    [No Abstract]   [Full Text] [Related]  

  • 22. Precision medicine in colorectal cancer.
    Aziz MA
    Saudi J Gastroenterol; 2019; 25(2):139-140. PubMed ID: 30900606
    [No Abstract]   [Full Text] [Related]  

  • 23. KRAS mutation screening in colorectal cancer: From paper to practice.
    Fakih MM
    Clin Colorectal Cancer; 2010 Jan; 9(1):22-30. PubMed ID: 20100685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacogenetics and tumor sensitivity of antineoplastic agents. Application to colorectal cancer].
    Milano G
    Rev Prat; 2008 May; 58(10):1056-9. PubMed ID: 18652401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.
    Ghiringhelli F; Richard C; Chevrier S; Végran F; Boidot R
    World J Gastroenterol; 2016 Dec; 22(48):10680-10686. PubMed ID: 28082821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
    Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
    Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
    [No Abstract]   [Full Text] [Related]  

  • 27. Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.
    Furtado LV; Samowitz WS
    Virchows Arch; 2017 Aug; 471(2):235-242. PubMed ID: 28551725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards the era of precision medicine in metastatic colorectal cancer.
    Napolitano S; Troiani T; Martinelli E; Ciardiello F
    ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32220949
    [No Abstract]   [Full Text] [Related]  

  • 29. Somatic Mutation Analysis of Human Cancers: Challenges in Clinical Practice.
    Tsongalis GJ; Coleman WB
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S60-S66. PubMed ID: 28921651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personalizing pancreatic cancer organoids with hPSCs.
    Zhang HC; Kuo CJ
    Nat Med; 2015 Nov; 21(11):1249-51. PubMed ID: 26540385
    [No Abstract]   [Full Text] [Related]  

  • 31. Retrospective Study of the Predictive Value of Target Now in Systemic Therapy for Metastatic Colorectal and Gastric Carcinomas.
    Cohen JE; Cohen Y; Peretz T; Hubert A
    Isr Med Assoc J; 2015 Oct; 17(10):612-5. PubMed ID: 26665314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is precision medicine ready for use in breast cancer?
    Pusztai L
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):964-966. PubMed ID: 28212357
    [No Abstract]   [Full Text] [Related]  

  • 33. Patient-tailored colorectal cancer care: a challenge within the context of evidence based guidelines.
    Tanis PJ
    Colorectal Dis; 2017 Jun; 19(6):521. PubMed ID: 28574658
    [No Abstract]   [Full Text] [Related]  

  • 34. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
    Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW
    World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.
    Zhang CM; Lv JF; Gong L; Yu LY; Chen XP; Zhou HH; Fan L
    Int J Environ Res Public Health; 2016 Sep; 13(9):. PubMed ID: 27618077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of patients with colorectal liver metastasis in eleven questions and answers.
    Andres A; Majno P; Terraz S; Morel P; Roth A; Rubbia-Brandt L; Schiffer E; Ris F; Toso C
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1277-1290. PubMed ID: 27744725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy.
    Perego P; Robert J
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):5-18. PubMed ID: 26589793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should oncologists be aware in their clinical practice of KRAS molecular analysis?
    Santini D; Galluzzo S; Gaeta L; Zoccoli A; Riva E; Ruzzo A; Vincenzi B; Graziano F; Loupakis F; Falcone A; Muda AO; Tonini G
    J Clin Oncol; 2011 Mar; 29(8):e206-7; author reply e208-9. PubMed ID: 21263083
    [No Abstract]   [Full Text] [Related]  

  • 39. RAS testing in metastatic colorectal cancer: advances in Europe.
    Van Krieken JH; Rouleau E; Ligtenberg MJ; Normanno N; Patterson SD; Jung A
    Virchows Arch; 2016 Apr; 468(4):383-96. PubMed ID: 26573425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis.
    Blom K; Nygren P; Larsson R; Andersson CR
    SLAS Technol; 2017 Jun; 22(3):306-314. PubMed ID: 28378608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.